{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:42:28Z","timestamp":1792460548390,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijgc.2025.101681","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T13:25:44Z","timestamp":1738329944000},"page":"101681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Controversies in the management of clear cell carcinoma of the uterus and ovary"],"prefix":"10.1016","volume":"35","author":[{"given":"Manavi","family":"Sachdeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-1515","authenticated-orcid":false,"given":"Felix","family":"Blanc-Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"David","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101681_bib2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","article-title":"Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers","volume":"109","author":"Chan","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2012.04.021","article-title":"Clear cell carcinoma of the ovary: a review of the literature","volume":"126","author":"del Carmen","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ygyno.2022.01.012","article-title":"Clear cell carcinoma of the endometrium","volume":"164","author":"Bogani","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101681_bib7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101681_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/PAP.0b013e31826663b1","article-title":"Clear cell carcinoma of the female Genital tract (not everything is as clear as it seems)","volume":"19","author":"Offman","year":"2012","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00004347-200107000-00008","article-title":"Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract","volume":"20","author":"Vang","year":"2001","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00004347-200404000-00004","article-title":"WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, Fallopian tube, ovary, and endometrium","volume":"23","author":"Acs","year":"2004","journal-title":"Int J Gynecol Pathol"},{"issue":"20","key":"10.1016\/j.ijgc.2025.101681_bib11","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-24-1205","article-title":"Unveiling commonalities: exploring\u00a0shared characteristics in clear-cell carcinomas of the gynecologic tract","volume":"30","author":"Blanc-Durand","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101681_bib12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","article-title":"Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma","volume":"174","author":"Kuo","year":"2009","journal-title":"Am J Pathol"},{"issue":"6001","key":"10.1016\/j.ijgc.2025.101681_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.ijgc.2025.101681_bib14","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/cncr.30745","article-title":"Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing","volume":"123","author":"Le Gallo","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101681_bib15","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.ajpath.2017.06.012","article-title":"Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks","volume":"187","author":"Murakami","year":"2017","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101681_bib16","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.3802\/jgo.2024.35.e69","article-title":"Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience","volume":"35","author":"Wijaya","year":"2024","journal-title":"J Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101681_bib17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.2013.35","article-title":"The clinicopathologic significance of p53 and\u00a0BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium","volume":"26","author":"Fadare","year":"2013","journal-title":"Mod Pathol"},{"issue":"18","key":"10.1016\/j.ijgc.2025.101681_bib18","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","article-title":"Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer","volume":"11","author":"Zorn","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101681_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021121","article-title":"Identification of novel therapeutic targets in microdissected clear cell ovarian cancers","volume":"6","author":"Stany","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygyno.2007.03.041","article-title":"Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma","volume":"106","author":"Lee","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib21","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2016.27.e5","article-title":"Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012","volume":"27","author":"Kim","year":"2016","journal-title":"J Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101681_bib22","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/jog.13450","volume":"43","author":"Saito","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101681_bib23","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e81","article-title":"Uterine clear cell carcinoma risk in White versus non-white US subpopulations: does race matter?","volume":"31","author":"Chow","year":"2020","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/jwh.2008.1171","article-title":"Racial and ethnic variations in the incidence of cancers of the uterine corpus, United States, 2001\u20132003","volume":"18","author":"Sabatino","year":"2009","journal-title":"J Womens Health (Larchmt)"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101681_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(11)70404-1","article-title":"Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case\u2013control studies","volume":"13","author":"Pearce","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2025.101681_bib26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1186\/s12885-015-1821-9","article-title":"Endometriosis as a risk factor for ovarian or endometrial cancer \u2014 results of a hospital-based case\u2013control study","volume":"15","author":"Burghaus","year":"2015","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.ijgc.2025.101681_bib27","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101681_bib28","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/s41379-021-00861-3","article-title":"Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma","volume":"34","author":"Murakami","year":"2021","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101681_bib29","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1177\/1933719117704909","article-title":"Role of oxidative stress in epigenetic modification in endometriosis","volume":"24","author":"Ito","year":"2017","journal-title":"Reprod Sci"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib30","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1530\/JME-17-0227","article-title":"Dysfunctional signaling underlying endometriosis: current state of knowledge","volume":"60","author":"Cho","year":"2018","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ygyno.2016.07.095","article-title":"Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study","volume":"143","author":"Mogensen","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s12905-022-02028-x","article-title":"The association between endometriosis and risk of endometrial cancer and breast cancer: a meta-analysis","volume":"22","author":"Ye","year":"2022","journal-title":"BMC Womens Health"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101681_bib33","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance\u00a0to platinum-based chemotherapy","volume":"88","author":"Sugiyama","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ygyno.2012.02.016","article-title":"Prognostic determinants in patients with uterine and ovarian clear carcinoma","volume":"125","author":"Rauh-Hain","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101681_bib35","first-page":"428","article-title":"Clear cell endometrial cancer: a CTF multicentre Italian study","volume":"36","author":"Maggino","year":"2015","journal-title":"Eur J Gynaecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101681_bib36","first-page":"1327","article-title":"Clear cell carcinoma of the endometrium: a biological and clinical enigma","volume":"30","author":"Gadducci","year":"2010","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101681_bib38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7150\/jca.11242","article-title":"Prognostic significance of lymphovascular space invasion in epithelial ovarian cancer","volume":"6","author":"Chen","year":"2015","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12957-024-03324-6","article-title":"The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis","volume":"22","author":"Liu","year":"2024","journal-title":"World J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian cancer, version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijgc.2025.101681_bib41","article-title":"Systematic lymphadenectomy and oncological outcomes of women with apparent early-stage clear cell carcinoma of the endometrium: a multi-institutional cohort study","volume":"12","author":"Tian","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ygyno.2017.05.016","article-title":"A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer","volume":"146","author":"Soliman","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2017.05.027","article-title":"Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations","volume":"146","author":"Holloway","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101681_bib44","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN guidelines\u00ae insights: ovarian cancer. version 3.2022","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101681_bib45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.101681_bib46","article-title":"Impact of adjuvant chemotherapy on FIGO Stage I ovarian clear cell carcinoma: a systematic review and meta-analysis","volume":"12","author":"Yin","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib47","first-page":"293","article-title":"Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: a systematic review and meta-analysis","volume":"157","author":"Bogani","year":"2020","journal-title":"Gynecol\u00a0Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101681_bib48","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib49","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2016.12.004","article-title":"Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma \u2013 a multi-institutional cohort","volume":"144","author":"Prendergast","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101681_bib50","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.ijgc.2025.101681_bib51","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101681_bib52","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO Guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ijgc.2025.101681_bib53","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: a report from the Australian ovarian cancer study group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ijgc.2025.101681_bib54","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.ijgc.2025.101681_bib55","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1016\/j.ijgc.2025.101681_bib56","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ijgc.2025.101681_bib57","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101681_bib58","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/JCO.2022.40.16_suppl.5502","article-title":"Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma: a multicenter, retrospective analysis","volume":"40","author":"Seki","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101681_bib59","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1200\/JCO.2022.40.16_suppl.5565","article-title":"A multicenter phase II randomized trial of durvalumab (D) versus physician\u2019s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3)","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.ijgc.2025.101681_bib60","first-page":"A127.2","article-title":"596 A randomised phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium. (NICCC\/ENGOT-OV36)","volume":"30","author":"Glasspool","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2025.101681_bib61","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1200\/jco.2014.32.15_suppl.5548","article-title":"Analysis of outcomes in patients (pts) with recurrent ovarian clear cell carcinoma (ROCCC): time to rethink our approach to treatment","volume":"32","author":"Tan","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib62","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib63","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ygyno.2021.07.005","article-title":"ARID1A mutation\/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer","volume":"162","author":"Kuroda","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the Phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib65","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/path.5769","article-title":"A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma","volume":"255","author":"Heong","year":"2021","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101681_bib66","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.3390\/cancers13102434","article-title":"Predictive and prognostic value of microsatellite instability in gynecologic cancer (endometrial and ovarian)","volume":"13","author":"Evrard","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib67","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.ijgc.2025.101681_bib68","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized Phase II trial of Nivolumab versus Nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101681_bib69","doi-asserted-by":"crossref","first-page":"S783","DOI":"10.1016\/j.annonc.2022.07.649","article-title":"521MO Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): phase II PEACOCC trial","volume":"33","author":"Kristeleit","year":"2022","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101681_bib70","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101681_bib71","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1016\/j.ijgc.2025.101681_bib72","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin\u2013paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101681_bib73","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.annonc.2024.04.007","article-title":"MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy","volume":"35","author":"Pignata","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.101681_bib74","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/j.annonc.2024.08.775","article-title":"713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: results from the phase II MoST-CIRCUIT trial","volume":"35","author":"Klein","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 17","key":"10.1016\/j.ijgc.2025.101681_bib75","doi-asserted-by":"crossref","first-page":"LBA5500","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500","article-title":"Final results of BrUOG 354: a randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas","volume":"42","author":"Dizon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"10.1016\/j.ijgc.2025.101681_bib76","doi-asserted-by":"crossref","first-page":"CT162","DOI":"10.1158\/1538-7445.AM2023-CT162","article-title":"Abstract CT162: a phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the clear cell ovarian, endometrial, cervical cancer cohorts","volume":"83","author":"Chae","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijgc.2025.101681_bib77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2024.03.027","article-title":"Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: an NRG oncology study GY016","volume":"186","author":"Gien","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101681_bib78","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib79","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijgc.2025.101681_bib80","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijgc.2025.101681_bib81","doi-asserted-by":"crossref","first-page":"S783","DOI":"10.1016\/j.annonc.2022.07.650","article-title":"522MO Preliminary results of sintilimab (Sin)+bevacizumab (Bev) in recurrent\/persistent ovarian clear cell carcinoma (INOVA): a multicenter, single-arm, phase II trial","volume":"33","author":"Liu","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.101681_bib82","doi-asserted-by":"crossref","first-page":"S729","DOI":"10.1016\/j.annonc.2021.08.1169","article-title":"726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician\u2019s choice in patients with advanced endometrial cancer (Study 309\/KEYNOTE-775)","volume":"32","author":"Colombo","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.101681_bib83","author":"Ngoi","year":"2024","journal-title":"Pembrolizumab Plus Lenvatinib (PL) in Recurrent Clear Cell Gynecological Cancer (CCGC): Phase II LARA Trial (GCGS-OV4\/ APGOT-OV3)"},{"key":"10.1016\/j.ijgc.2025.101681_bib84","doi-asserted-by":"crossref","first-page":"S511","DOI":"10.1016\/j.annonc.2023.09.1926","article-title":"747MO First results from the ENGOT-GYN2\/GOG-3051\/BOUQUET phase II biomarker-directed platform study: cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent\/recurrent rare epithelial ovarian cancer (eOC)","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101681_bib85","doi-asserted-by":"crossref","first-page":"TPS5627","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5627","article-title":"A three-arm randomized phase II study of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynecological clear cell carcinoma: DOVE (APGOT-OV7\/ENGOT-ov80 study)","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101681_bib86","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.ijgc.2025.101681_bib87","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1158\/0008-5472.CAN-05-1225","article-title":"The p270 (ARID1A\/SMARCF1) subunit of mammalian SWI\/SNF-related complexes is essential for normal cell cycle arrest","volume":"65","author":"Nagl","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib88","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ygyno.2019.10.002","article-title":"Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma","volume":"155","author":"Kuroda","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101681_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100814","article-title":"34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: results from the ENGOT\/GYN1\/NCRI ATARI trial","volume":"8","author":"Banerjee","year":"2023","journal-title":"ESMO Open"},{"issue":"24","key":"10.1016\/j.ijgc.2025.101681_bib91","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-18-1244","article-title":"A clinical and molecular phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the Princess Margaret Phase II consortium","volume":"24","author":"Lheureux","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib92","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ijgc.2025.101681_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1136248","article-title":"ARID1A in cancer: friend or foe?","volume":"13","author":"Fontana","year":"2023","journal-title":"Front Oncol"},{"issue":"suppl 10","key":"10.1016\/j.ijgc.2025.101681_bib94","first-page":"x46","article-title":"Update on nonserous ovarian cancer trials","volume":"24","author":"Fujiwara","year":"2013","journal-title":"Ann\u00a0Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib95","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2022.10.006","article-title":"A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: an NRG oncology trial","volume":"167","author":"Farley","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101681_bib96","first-page":"527","article-title":"An attempt to develop a new treatment strategy for rare refractory gynecological malignancies: the Japanese Gynecologic Oncology Group","volume":"6","author":"Shigeta","year":"2023","journal-title":"JMA"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101681_bib97","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.13704","article-title":"HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation","volume":"73","author":"Koopman","year":"2018","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101681_bib98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101681_bib99","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2023.41.16_suppl.3014","article-title":"Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: results from a phase 2 basket trial (HERALD\/EPOC1806)","volume":"41","author":"Taniguchi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101681_bib100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","article-title":"Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101681_bib101","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1200\/JCO.2023.41.16_suppl.3082","article-title":"Initial results of dose finding in a first-in-human phase 1 study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors","volume":"41","author":"Konecny","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101681_bib102","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-23-0287","article-title":"Raludotatug deruxtecan, a CDH6-targeting antibody\u2013drug conjugate with a DNA topoisomerase I inhibitor DXd, is efficacious in human ovarian and kidney cancer models","volume":"23","author":"Suzuki","year":"2024","journal-title":"Mol Cancer Ther"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25002063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25002063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:57:57Z","timestamp":1762354677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25002063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1048891X25002063"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101681","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in the management of clear cell carcinoma of the uterus and ovary","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101681"}}